Meisner Lara 4
4 · Bicara Therapeutics Inc. · Filed Sep 17, 2025
Insider Transaction Report
Form 4
Meisner Lara
Chief Legal Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-15−9,744→ 87,699 totalExercise: $5.45Exp: 2033-12-14→ Common Stock (9,744 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-15−6,085→ 54,769 totalExercise: $5.45Exp: 2033-12-14→ Common Stock (6,085 underlying) - Exercise/Conversion
Common Stock
2025-09-15$5.45/sh+15,829$86,268→ 15,829 total - Sale
Common Stock
2025-09-15$11.49/sh−15,829$181,875→ 0 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.34 to $11.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.
- [F4]25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.